Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28893
IPSCIO Record ID: 3603
LungAlertâ„¢ is a novel test that identifies patients at risk of lung cancer at the early stages of the disease. The test detects a cancer-associated sugar in a sample of sputum (phlegm), which is obtained in the doctorâ€™s office by coughing into a cup. Currently, there is no screening test for lung cancer that has proven to save lives.
IPSCIO Record ID: 27476
The EPN Scan device is designed to provide further information on whether a lung legion may be cancerous after detection by CT Scan.
IPSCIO Record ID: 256273
This agreement includes a non-exclusive grant by Licensee to Licensor.
The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.
Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.
IPSCIO Record ID: 383585
Licensor grants a non-exclusive worldwide license, with the right to grant sublicenses, under the Licensed IP and Licensor Technology in the Field to develop, have developed, make, have made, use, have used, sell, have sold, import, co have imported, offer for sale and have offered for sale Licensed Products in the Territory. This will secure Licensees non-exclusive access to Licensors Collect technology.
Licensor grants the right to extend the right to use such Licensed Product to their customers of the Licensed Product on which the royalty is paid, label license.
Licensed Products encompass the components Collect, Select and Detect.
NAT is nucleic acid amplification technology.
Platforms shall mean technologies employed in Licensed Products as well as competitive products based on the same or essentially similar technologies (employing the same scientific or technical principles), used in LIPA, 4â€¢MAT and Luminex systems or certain, identified Real Time PCR technology.
Colon cancer Method and Kit for the diagnosis of therapy of colon cancer
Breast cancer Method and Kit for the diagnosis of therapy of breast cancer
Core patent Method and diagnosis kit for selection and/or quantitative detection of cells
Reagency and method for preventing time-dependent RNA -expression in biological cells
IPSCIO Record ID: 223141
applications and patents.
W003023057 (PCT /EP02/05489) – Method and Diagnosis Kit for Selection and/or for Qualitative and/or Quantitative Detection of Cells
Licensed Products shall mean in-vitro diagnostic assays to isolate, detect, identify, quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of prostate cancer and/or bladder cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the AdnaGen Patent Rights.
'Group 1 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of kidney cancer, cervical cancer, and/or ovarian cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.
'Group 2 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of lung cancer, colon cancer, and/or breast cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.
IPSCIO Record ID: 315834
For the Research, Licensee shall perform primary testing associated with a validation study of its laboratory -developed test using the Licensed Technology in connection with MD Anderson Cancer Center or an equivalent academic cancer center (with the exception of tissue biopsy) including expression testing, the PSA and send-out of the PCA-3, the Validation Study. Licensee shall have the right to perform research on remnants after all testing required for the Validation Study is completed, and will be provided reasonable access to the patient data related to the applicable samples. Licensor shall obtain IRB approval for the study with MD Anderson Cancer Center by February 28, 2009 or, with an equivalent academic institution by June 30, 2009.
For the Purchasing Rights, upon issuance of FDA clearance or approval of an in vitro diagnostic kit using the Licensed Technology (IVD Kit), Licensee shall have the obligation to purchase IVD Kits for reference laboratory use from Licensorâ€™s designated manufacturer or distributor pursuant to a purchasing agreement between Licensee and the applicable manufacturer or distributor, provided however that Licensor shall negotiate to cause such manufacturer or distributor to provide Most Favored Terms to Licensee.
The patents include
Method of Identifying Patterns in Biological Systems and Uses Thereof;
Biomarkers Overexpressed in Prostate Cancer;
Biomarkers Upregulated in Prostate Cancer; and,
Methods for Screening, Predicting and Monitoring Prostate Cancer.
Licensees focus is developing a test for and performing clinical laboratory diagnostic testing using gene biomarkers detected in patient urine samples for differentiating clinically significant prostate cancer from other prostate conditions.
IPSCIO Record ID: 5622
Licensee and its Affiliates shall have the right to use the Trademarks, solely in connection with the use of the Colon 101 ELISA Test.
CDX field means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.
RDX Field means use in vitro diagnostic testing services in Clinical Trials.
The Licensee shall have the right to use the Trademarks.
'RDX Field' means use in in vitro diagnostic testing services in Clinical Trials.